GDF15 and LCN2 for early detection and prognosis of pancreatic cancer
Our findings indicate that GDF15 holds promise as a biomarker for early detection and prognosis of PDAC, while LCN2 could strengthen diagnostic panels.
Authors
- Daniel L. Marks (ORCID: https://orcid.org/0000-0003-2675-7047)
- Abigail C. Buenafe
- Xinxia Zhu (ORCID: https://orcid.org/0009-0009-4041-1561)
- Mason A. Norgard
- Ariana Sattler (ORCID: https://orcid.org/0000-0003-1699-4743)
- Xiaolin Li (ORCID: https://orcid.org/0000-0001-9570-8631)
- Parham Diba (ORCID: https://orcid.org/0000-0003-1014-510X)
- Brennan Olson (ORCID: https://orcid.org/0000-0003-2803-5363)
- Sara Protzek
- Aaron J. Grossberg (ORCID: https://orcid.org/0000-0003-4690-4948)
- Peter R. Levasseur
- Tetiana Korzun (ORCID: https://orcid.org/0000-0002-5871-2778)
- Dove Keith (ORCID: https://orcid.org/0000-0001-6104-3264)
- Ju Li (ORCID: https://orcid.org/0000-0002-7841-8058)
Institutions
- Oregon Health & Science University (US)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.tranon.2024.102129
- Citations
- 6
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.82
Funders
- Oregon Health and Science University
- National Institutes of Health
- Oregon Clinical and Translational Research Institute
- Knight Cancer Institute, Oregon Health and Science University
- National Cancer Institute